Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 6/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 7/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31372427 | 1.00 | PPARA (0.60) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL15569246 | 1.00 | PPARA (0.60) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL8138593 | 0.96 | CTSS (0.59) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL16464139 | 0.92 | CTSK (0.54) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL16464142 | 0.92 | CTSK (0.54) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL30447913 | 0.91 | PPARA (0.57) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL8129917 | 0.91 | CTSS (0.57) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL7518373 | 0.90 | PPARA (0.74) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL6436359 | 0.90 | CTSK (0.60) | PPARACTSSSYKCTSKCTSL | |
| SCHEMBL19853661 | 0.90 | PPARA (0.74) | PPARACTSSSYKCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464321-B1 | PROTEASOME INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-11345724-B2 | Proteasome inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20200325171-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-15 | — | — | US | disclosed |
| WO-2018112078-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018057453-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | AMGEN INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2017211818-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| US-8716322-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | PPARA 2426/4885CTSS 1116/4885SYK 3227/4885 |
| US-20200325171-A1 | PROTEASOME INHIBITORS | PSMB1, PSMB2, PSMB5 | PPARA 3989/4885CTSS 1444/4885SYK 3844/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | PPARA 3489/4885CTSS 125/4885SYK 2473/4885 |
| US-11345724-B2 | Proteasome inhibitors | PSMB1, PSMB2, PSMB5 | PPARA 4206/4885CTSS 1305/4885SYK 3771/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | PPARA 3784/4885CTSS 177/4885SYK 2824/4885 |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | PPARA 2055/4885CTSS 79/4885SYK 4043/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | PPARA 2465/4885CTSS 1197/4885SYK 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.